Cargando…

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study

BACKGROUND: There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. METHODS: Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Gori, Stefania, Inno, Alessandro, Rossi, Valentina, Turazza, Monica, Fiorio, Elena, Fabi, Alessandra, Bisagni, Giancarlo, Foglietta, Jennifer, Santini, Daniele, Pavese, Ida, Pellegrino, Arianna, Zambelli, Alberto, Vici, Patrizia, Leonardi, Vita, Barni, Sandro, Saracchini, Silvana, Bogina, Giuseppe, Marchetti, Fabiana, Duranti, Simona, Lunardi, Gianluigi, Montemurro, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880338/
https://www.ncbi.nlm.nih.gov/pubmed/27224517
http://dx.doi.org/10.1371/journal.pone.0156221
_version_ 1782433789926965248
author Gori, Stefania
Inno, Alessandro
Rossi, Valentina
Turazza, Monica
Fiorio, Elena
Fabi, Alessandra
Bisagni, Giancarlo
Foglietta, Jennifer
Santini, Daniele
Pavese, Ida
Pellegrino, Arianna
Zambelli, Alberto
Vici, Patrizia
Leonardi, Vita
Barni, Sandro
Saracchini, Silvana
Bogina, Giuseppe
Marchetti, Fabiana
Duranti, Simona
Lunardi, Gianluigi
Montemurro, Filippo
author_facet Gori, Stefania
Inno, Alessandro
Rossi, Valentina
Turazza, Monica
Fiorio, Elena
Fabi, Alessandra
Bisagni, Giancarlo
Foglietta, Jennifer
Santini, Daniele
Pavese, Ida
Pellegrino, Arianna
Zambelli, Alberto
Vici, Patrizia
Leonardi, Vita
Barni, Sandro
Saracchini, Silvana
Bogina, Giuseppe
Marchetti, Fabiana
Duranti, Simona
Lunardi, Gianluigi
Montemurro, Filippo
author_sort Gori, Stefania
collection PubMed
description BACKGROUND: There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. METHODS: Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. RESULTS: At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p<0.001). Multivariate analysis revealed the benefit of lapatinib-based therapy in terms of PFS and OS was significantly associated with time-to-progression (TTP) on prior first-line trastuzumab-based therapy. In particular, each additional month on first-line trastuzumab based therapy was associated with a reduction in hazard of progression and death after the initiation of lapatinib-based therapy of 2% and 4%, respectively. CONCLUSIONS: A longer TTP to first line trastuzumab seems to predict a prolonged PFS and OS with subsequent lapatinib and capecitabine.
format Online
Article
Text
id pubmed-4880338
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48803382016-06-09 Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study Gori, Stefania Inno, Alessandro Rossi, Valentina Turazza, Monica Fiorio, Elena Fabi, Alessandra Bisagni, Giancarlo Foglietta, Jennifer Santini, Daniele Pavese, Ida Pellegrino, Arianna Zambelli, Alberto Vici, Patrizia Leonardi, Vita Barni, Sandro Saracchini, Silvana Bogina, Giuseppe Marchetti, Fabiana Duranti, Simona Lunardi, Gianluigi Montemurro, Filippo PLoS One Research Article BACKGROUND: There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. METHODS: Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. RESULTS: At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p<0.001). Multivariate analysis revealed the benefit of lapatinib-based therapy in terms of PFS and OS was significantly associated with time-to-progression (TTP) on prior first-line trastuzumab-based therapy. In particular, each additional month on first-line trastuzumab based therapy was associated with a reduction in hazard of progression and death after the initiation of lapatinib-based therapy of 2% and 4%, respectively. CONCLUSIONS: A longer TTP to first line trastuzumab seems to predict a prolonged PFS and OS with subsequent lapatinib and capecitabine. Public Library of Science 2016-05-25 /pmc/articles/PMC4880338/ /pubmed/27224517 http://dx.doi.org/10.1371/journal.pone.0156221 Text en © 2016 Gori et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gori, Stefania
Inno, Alessandro
Rossi, Valentina
Turazza, Monica
Fiorio, Elena
Fabi, Alessandra
Bisagni, Giancarlo
Foglietta, Jennifer
Santini, Daniele
Pavese, Ida
Pellegrino, Arianna
Zambelli, Alberto
Vici, Patrizia
Leonardi, Vita
Barni, Sandro
Saracchini, Silvana
Bogina, Giuseppe
Marchetti, Fabiana
Duranti, Simona
Lunardi, Gianluigi
Montemurro, Filippo
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
title Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
title_full Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
title_fullStr Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
title_full_unstemmed Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
title_short Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
title_sort predictive factors of lapatinib and capecitabine activity in patients with her2-positive, trastuzumab-resistant metastatic breast cancer: results from the italian retrospective multicenter herlapac study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880338/
https://www.ncbi.nlm.nih.gov/pubmed/27224517
http://dx.doi.org/10.1371/journal.pone.0156221
work_keys_str_mv AT goristefania predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT innoalessandro predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT rossivalentina predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT turazzamonica predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT fiorioelena predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT fabialessandra predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT bisagnigiancarlo predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT fogliettajennifer predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT santinidaniele predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT paveseida predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT pellegrinoarianna predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT zambellialberto predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT vicipatrizia predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT leonardivita predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT barnisandro predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT saracchinisilvana predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT boginagiuseppe predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT marchettifabiana predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT durantisimona predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT lunardigianluigi predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy
AT montemurrofilippo predictivefactorsoflapatinibandcapecitabineactivityinpatientswithher2positivetrastuzumabresistantmetastaticbreastcancerresultsfromtheitalianretrospectivemulticenterherlapacstudy